Shattuck Labs Stock Quote STTK - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

4.41

Bid

4.41

Ask

4.43

Volume

207,375

4.34 Day's Range 4.69

1.3301 52 Week Range 11.76

Market Cap

220.636M

Previous Close

4.64

Open

4.65

Last Trade

4.41

Last Trade Time

14:41:23

Financial Volume

$ 940,226

VWAP

4.5339

Average Volume (3m)

388,943

Shares Outstanding

47,550,872

Dividend Yield

PE Ratio

-2.41

Earnings Per Share (EPS)

-1.84

Revenue

1.66M

Net Profit

-87.3M

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restor... Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.shattucklabs.com

Headquarters

Dover, Delaware, USA

Founded

1970

Shattuck Labs Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker STTK. The last closing price for Shattuck Labs was $4.64. Over the last year, Shattuck Labs shares have traded in a share price range of $ 1.3301 to $ 11.76.

Shattuck Labs currently has 47,550,872 shares outstanding. The market capitalization of Shattuck Labs is $220.64 million. Shattuck Labs has a price to earnings ratio (PE ratio) of -2.41.

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional...

Form 8-K - Current report

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuke

– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median...

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional...

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Mye

- Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck...

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the Eu

– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML...

Form 4 - Statement of changes in beneficial ownership of securities

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.34	8.35380835381	4.07	4.99	3.88	626678	4.63700803	CS
4	0.23	5.5023923445	4.18	4.99	3.345	478250	4.12024492	CS
12	-5.41	-55.0916496945	9.82	11.76	3.345	388943	6.46726908	CS
26	-4.09	-48.1176470588	8.5	11.76	3.345	350804	7.8768303	CS
52	1.66	60.3636363636	2.75	11.76	1.3301	587104	6.32004846	CS
156	-18.18	-80.4780876494	22.59	24.27	1.3301	293438	6.91194483	CS
260	-14.2	-76.3030628694	18.61	60.5162	1.3301	273189	10.6868984	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SERVServe Robotics Inc	$ 7.5454 (186.90%)	221.62M
AUGXAugmedix Inc	$ 2.27 (147.71%)	18.91M
SXTP60 Degrees Pharmaceuticals Inc	$ 0.36335 (47.70%)	185.74M
PSNLPersonalis Inc	$ 3.6187 (47.70%)	17.15M
VRPXVirpax Pharmaceuticals Inc	$ 1.77 (38.28%)	45.26M
SPWRSunPower Corporation	$ 0.6904 (-54.28%)	92.74M
HYZNHyzon Motors Inc	$ 0.1433 (-49.54%)	20.5M
MEDSTRxADE Health Inc	$ 14.38 (-35.86%)	172.99k
KITTNauticus Robotics Inc	$ 0.0901 (-30.10%)	24.96M
SILOSilo Pharma Inc	$ 2.53 (-27.09%)	11.31M
SERVServe Robotics Inc	$ 7.5454 (186.90%)	221.62M
SXTP60 Degrees Pharmaceuticals Inc	$ 0.36335 (47.70%)	185.74M
SQQQProShares UltraPro Short QQQ	$ 8.4784 (3.02%)	148.65M
NVDANVIDIA Corporation	$ 117.98 (-2.57%)	142.73M
SPWRSunPower Corporation	$ 0.6904 (-54.28%)	88.11M